▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1954 by analyst upside · 2026-06-27
RMD
ResMed Inc.
Healthcare · Market Cap $29B · P/E 19.3x
ANALYST PRICE TARGET
+30.1%
implied upside to consensus target
Current Price $200.29
Consensus Target $260.6
Bull Target $325.0
Bear Target $180.0
Analysts Covering 15
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
6
Hold
6
Sell
1
52-Week Low $180.27
52-Week High $293.81
YTD Return -17.8%
FUNDAMENTALS
Market Cap $29B
P/E Ratio (TTM) 19.3x
Forward P/E 16.5x
EPS (TTM) $10.37
PEG Ratio 1.16
Dividend Yield 1.21%
Revenue (TTM) $5.5B
Profit Margin 27.4%
52-WEEK RANGE
52-Week Low $180.27
52-Week High $293.81
Current Price $200.29
Bear Target $180.0
Bull Target $325.0
● Now $200.29 ● Target $260.6
TRADING DATA
Avg Volume 1.4M
YTD Return -17.8%
Analyst Count 15
Consensus Buy
Upside to Target +30.1%
Last Updated 2026-06-27

ANALYST SUMMARY

ResMed Inc. (RMD) is currently trading at $200.29 with a Wall Street consensus price target of $260.6, implying potential upside of 30.1% over the next 12 months. 15 analysts currently cover RMD, with a consensus rating of Buy — 53% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $325.0, while the most cautious has a target of $180.0.

RMD operates in the Healthcare sector with a market capitalisation of $29B. The stock is down 17.8% year-to-date and is currently trading near the lower end of its 52-week range of $180.27 – $293.81.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GEHC +21.3%
GE HealthCare Technologies Inc.
$30B · P/E 15.8x · Buy
PHG +23.8%
Koninklijke Philips N.V.
$26B · P/E 24.0x · Buy
DXCM +21.5%
DexCom, Inc.
$27B · P/E 30.1x · Buy
FSNUY +38.7%
Fresenius SE & Co. KGaA
$26B · P/E 15.1x · Buy
IQV +18.0%
IQVIA Holdings Inc.
$32B · P/E 23.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for RMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley ↓ Downgrade
Overweight → Equal-Weight 2026-06-17 Building track record
Citigroup — Reiterated
Buy → Buy 2026-06-15 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-01 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2026-05-01 Building track record
Keybanc — Reiterated
Overweight → Overweight 2026-04-27 Building track record
Citigroup — Reiterated
Buy → Buy 2026-04-09 Building track record
Citigroup — Reiterated
Buy → Buy 2026-02-02 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-01-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →